Back to results
US 10,137,109 B2Granted
Carbazole compounds and therapeutic uses of the compounds
AssigneeIncuron, LLC
InventorsJohn Tucker, Sergey Sviridov, Leonid Brodsky, Catherine Burkhart, Andrei Purmal, Katerina Gurova, Andrei Gudkov
Life of this patent
Estimating the term…
Abstract
Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).
Claims19
A method for treating melanoma, comprising intraarterially administering to a patient in need thereof an effective amount of a compound of a structural formula:
- wherein Ra is selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, ORe, N(Re)2, and SRe;
- alternatively, either Ra and R1 or NRe and R1 together with the carbon atoms to which they are attached form a five or six-membered aliphatic carbocyclic or heterocyclic ring;
- Rb is selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, ORe, N(Re)2, and SRe, alternatively, either Rb and R6 or NRe and R6 together with the carbon atoms to which they are attached form a five or six-membered aliphatic carbocyclic ring or a five or six-membered aliphatic carbocyclic or heterocyclic ring;
- Rc is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 hydroxyalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and C(═O)Re, or Rc and Rd are taken together to form a five, six, or seven-membered aliphatic ring, optionally containing an oxygen atom;
- Rd is selected from the group consisting of hydrogen, C1-6alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and C(═O)Re, or Rd and R7 together with the atoms to which they are attached form a five or six-membered aliphatic ring;
- Re, independently, is selected from the group consisting of hydrogen, C1-6alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, or two Re groups taken together with a nitrogen to which they are attached to form a five or six-membered aliphatic ring;
- R1, R2, R3, R4, R5, and R6, independently, are selected from the group consisting of hydrogen, C1-6alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, ORe, C(═O)Re, C(═O)ORe, OC(═O)Re, C(═O)N(Re)2, C(═O)NReSO2Re, N(Re)2, NReC(═O)Re, NReC(═O)N(Re)2, CN, NO2, CF3, OCF3, SRe, SORe, SO2N(Re)2, and OSO2CF3;
- R7 is selected from the group consisting of hydrogen, C1-6alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
- and
- n is 1, 2, 3, 4, or 5,
- or a pharmaceutically acceptable salt or hydrate thereof and
- wherein the intraarterial administration is intraarterial infusion.
9 more elements
A method for treating metastatic colon cancer, comprising intraarterially administering to a patient in need thereof an effective amount of a compound of a structural formula:
- wherein Ra is selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, ORe, N(Re)2, and SRe;
- alternatively, either Ra and R1 or NRe and R1 together with the carbon atoms to which they are attached form a five or six-membered aliphatic carbocyclic or heterocyclic ring;
- Rb is selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, ORe, N(Re)2, and SRe, alternatively, either Rb and R6 or NRe and R6 together with the carbon atoms to which they are attached form a five or six-membered aliphatic carbocyclic ring or a five or six-membered aliphatic carbocyclic or heterocyclic ring;
- Rc is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 hydroxyalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and C(═O)Re, or Rc and Rd are taken together to form a five, six, or seven-membered aliphatic ring, optionally containing an oxygen atom;
- Rd is selected from the group consisting of hydrogen, C1-6alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and C(═O)Re, or Rd and R7 together with the atoms to which they are attached form a five or six-membered aliphatic ring;
- Re, independently, is selected from the group consisting of hydrogen, C1-6alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, or two Re groups taken together with a nitrogen to which they are attached to form a five or six-membered aliphatic ring;
- R1, R2, R3, R4, R5, and R6, independently, are selected from the group consisting of hydrogen, C1-6alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, ORe, C(═O)Re, C(═O)ORe, OC(═O)Re, C(═O)N(Re)2, C(═O)NReSO2Re, N(Re)2, NReC(═O)Re, NReC(═O)N(Re)2, CN, NO2, CF3, OCF3, SRe, SORe, SO2N(Re)2, and OSO2CF3;
- R7 is selected from the group consisting of hydrogen, C1-6alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
- and
- n is 1, 2, 3, 4, or 5,
- or a pharmaceutically acceptable salt or hydrate thereof and
- wherein the intraarterial administration is intraarterial infusion.
9 more elements
A method for treating metastatic breast cancer, comprising intraarterially administering to a patient in need thereof an effective amount of a compound of a structural formula:
- wherein Ra is selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, ORe, N(Re)2, and SRe;
- alternatively, either Ra and R1 or NRe and R1 together with the carbon atoms to which they are attached form a five or six-membered aliphatic carbocyclic or heterocyclic ring;
- Rb is selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, ORe, N(Re)2, and SRe, alternatively, either Rb and R6 or NRe and R6 together with the carbon atoms to which they are attached form a five or six-membered aliphatic carbocyclic ring or a five or six-membered aliphatic carbocyclic or heterocyclic ring;
- Rc is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 hydroxyalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and C(═O)Re, or Rc and Rd are taken together to form a five, six, or seven-membered aliphatic ring, optionally containing an oxygen atom;
- Rd is selected from the group consisting of hydrogen, C1-6alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and C(═O)Re, or Rd and R7 together with the atoms to which they are attached form a five or six-membered aliphatic ring;
- Re, independently, is selected from the group consisting of hydrogen, C1-6alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, or two Re groups taken together with a nitrogen to which they are attached to form a five or six-membered aliphatic ring;
- R1, R2, R3, R4, R5, and R6, independently, are selected from the group consisting of hydrogen, C1-6alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, ORe, C(═O)Re, C(═O)ORe, OC(═O)Re, C(═O)N(Re)2, C(═O)NReSO2Re, N(Re)2, NReC(═O)Re, NReC(═O)N(Re)2, CN, NO2, CF3, OCF3, SRe, SORe, SO2N(Re)2, and OSO2CF3;
- R7 is selected from the group consisting of hydrogen, C1-6alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
- and
- n is 1, 2, 3, 4, or 5,
- or a pharmaceutically acceptable salt or hydrate thereof and
- wherein the intraarterial administration is intraarterial infusion.
9 more elements
Dependencies are inferred from the claim text.